Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects in Fed State

Launched by DONG-A ST CO., LTD. · Jun 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the body processes and responds to a medicine called DA-5222 when given in two different ways: either as a single dose or as three separate doses taken together. The study aims to understand how safe these dosing methods are and how the medicine behaves in healthy adults after they have eaten.

To join this study, participants need to be healthy adults with a body weight of at least 50 kg for men or 45 kg for women, and a body mass index (BMI) between 18 and 30, which means they should be within a normal to slightly overweight range. People with significant health problems, drug addiction, or allergies to medicines cannot take part. If you join, you will be asked to take the medicine while in a fed state (after eating), and the researchers will monitor your body’s response and check for any side effects to make sure the medicine is safe. This study is still not recruiting participants yet.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy volunteers
• • BMI between 18 and 30 kg/m2
• • Body weight: Male≥50kg, Female≥45kg
• • Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
• Exclusion Criteria:
• • Subjects with clinically significant medical history
• • Subjects with history of drug abuse or addicted
• • Subjects with allergy or drug hypersensitivity